DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy

Area of Science:

• Oncology
• Genetics
• Pharmacogenomics

Background:

• Platinum-based chemotherapy is a cornerstone treatment for advanced non-small cell lung cancer (NSCLC).
• Genetic variations, particularly single-nucleotide polymorphisms (SNPs) in DNA repair genes, can influence chemotherapy efficacy.
• ERCC1, ERCC2, and XRCC1 are key genes involved in DNA repair pathways, potentially impacting platinum sensitivity.

Purpose of the Study:

• To investigate the association between specific SNPs in ERCC1, ERCC2, and XRCC1 genes and the sensitivity of advanced NSCLC patients to platinum-based chemotherapy.
• To explore the potential of these SNPs as predictive biomarkers for treatment response.

Main Methods:

• A cohort of 89 advanced NSCLC patients treated with platinum-based chemotherapy was studied.
• DNA was extracted from peripheral lymphocytes to detect SNPs: ERCC1 Asn118Asn, ERCC2 Lys751Gln, and XRCC1 Arg399Gln.
• Treatment response rates were analyzed in relation to different genotypes.

Main Results:

• The overall response rate to chemotherapy was 29.2%.
• No significant association was found between ERCC1 Asn118Asn or ERCC2 Lys751Gln genotypes and treatment response.
• XRCC1 Arg399Gln genotype distribution differed significantly between responders and non-responders (P = 0.001).
• XRCC1 399Arg/Arg genotype carriers showed a higher response rate (OR = 4.81, P = 0.002).
• Combined favorable genotypes of ERCC1, ERCC2, and XRCC1 correlated with higher response rates.

Conclusions:

• The XRCC1 Arg399Gln polymorphism is significantly associated with platinum-based chemotherapy response in NSCLC patients.
• Combined polymorphisms in ERCC1, ERCC2, and XRCC1 may serve as predictive biomarkers for chemotherapy sensitivity in NSCLC.
• Further validation studies are warranted to confirm these findings for clinical application.